Prof. Stephen Nicholls discusses the results of a study that investigated the lipid-lowering effects of triple therapy with bempedoic acid, ezetimibe and statin as a new potential strategy for treating hypercholesterolemia.
A study using data from the Copenhagen General Population Study showed that cholesterol in VLDL explains 50% of the MI risk from apoB-containing lipoproteins. Triglycerides in VLDL explain 0%. With poll.
The DA VINCI study demonstrated that the majority of prescibed therapies for lipid-lowering in Europe is monotherapy with statins and only one-third of patients met their LDL-c goal described in the 2019 dyslipidemia guidelines. With poll.
Prof. Laufs discusses the role of triglycerides and Lp(a) in the context of residual risk.
Identifying and treating classic CV risk factors is important in patients with diabetes to reduce their CV risk. In this presentation, prof. Hobbs discusses the classic CV risk factors one by one.
EAS 2020 Prof. Stein gives an overview of studies with the small binding protein targeting PCSK9, named LIB003.
Prof. Mach explains the recommendations for pharmacological LDL-c lowering as described in the 2019 ESC/EAS guidelines for the management of dyslipidemia.
Prof. Klaus Parhofer discusses the role of hypertriglyceridemia in the setting of residual risk.
In this video, internist Kees Hovingh discusses why screening for FH is important and how to identify individual FH patients and their families. With question to test your knowledge.
Jorge Plutzky talks about an approach implemented in the Brigham and Women's Hospital, that uses an algorithm to select type of medication per individual to achieve target LDL-c levels.
In the past, there has been confusion about the relationship between HDL-c and CV risk and also between triglycerides and CV risk. Prof. Libby gives an update on what we know now about these lipids and CV risk.
At the end of the FOURIER trial, participants filled out a questionnaire on their memory, cognitive and executive function. No differences on cognition were noted between treatment groups.
Prof. Ray explains how he decides on the amount of LDL-c lowering that is needed in a given patient, and why he chooses this approach.
Learn how bempedoic acid an ACL inhibtor works in reducing LDL-c
A subanalysis of FOURIER found that patients with recent MI (<12 months) had greater relative and absolute treatment benefit of evolocumab than those with remote MI.
The new ESC/EAS Dyslipidaemia Guidelines focus on high-risk patients, and prof. Laufs shares evidence for the treatment recommendations. Test your knowledge
Robert Giugliano explains that very low LDL-c levels are safe, using data of recent clinical trials with LDL-c lowering drugs.
Prof. Landmesser shows data that form the rationale behind new guideline recommendations, among which the lower LDL-c target for patients at very high risk.
Thomas Gaziano presents data on worldwide trends in CV mortality and CV risk factors. He gives a brief update on different programs on CVD prevention, both in high and low income countries.
Prof. Lüscher paints a picture of how atherosclerosis has been a fact of human life throughout time, and the evolution of insights on how to lower LDL-c and its associated CV risk.
AHA 2019 A new tool, connected to the electronic patient files corrects for statin use (type and dose) to determine untreated LDL-c levels and the Dutch lipid score.
AHA 2019 The ORION-10 trial met all its primary and secundary efficacy endpoints, with a good safety profile, up to 17 months.
Prof. Knop gives an overview of potential mechanisms of action of GLP-1RAs to explain observed effects on glycemia, body weight, blood pressure and blood lipids.
Before listing the differences between the AHA/ACC 2018 and ESC/EAS 2019 dyslipidemia guidelines, prof. Ballantyne shares common themes and shared concept across the guidelines.
In the FOURIER trial, evolocumab reduced LDL-c by ~60% in patients with established CVD. Prof. Sabatine highlights subgroups of high-risk patients who benefit most from treatment with this PCSK9 inhibitor.
Prof. Kastelein discusses new strategies to target PCSK9, including twice-a-year injections of inclisiran and a newly developed oral PCSK9 inhibitor.
ESC 2019 Prof. François Mach presents results of the EVOPACS trial, showing decreased LDL-c levels with evolocumab vs. placebo at 8 weeks after ACS in patients with STEMI and NSTEMI.
ESC 2019 Prof. John Kastelein shares the results of the phase 3 ORION-11 trial with inclisiran in ASCVD and risk equivalent patients not at LDL-C goal.
ESC 2019 Prof. Alberico Catapano (Past President EAS) highlights the most important changes in risk classification and treatment goals for LDL-c according to total CV risk in the new 2019 ESC/EAS Dyslipidemia Guidelines.
ESC 2019 Prof. François Mach was co-chair of the Task Force that composed the new ESC/EAS Dyslipidemia Guidelines. He lists some of the changes compared to the previous version and explains why he supports the changes.
Lp(a) meeting Prof. Marcovina emphasizes the importance of considering apo(a) size polymorphism when measuring Lp(a) levels in patients and discusses the Lp(a) Standardization Program.
Lp(a) meeting Existing clinical LDL-c assays cannot distinguish LDL-c from Lp(a)-c. Dr. Yeang discusses how Lp(a)-c is included in LDL-c measurements and what the clinical impact of measuring Lp(a)-c can be.
Prof. Knop describes the possible mechanisms of CV/CKD risk reduction by GLP-1 receptor activation.
Lp(a) meeting Pia Kamstrup shares data of two general population studies that reveal the effects of elevated Lp(a) levels on CV events, and effects of Lp(a) risk genotypes, which are consistent with Lp(a) being a causal risk factor for CVD.
Lp(a) meeting Prof. Tsimikas discusses the phase 2 apo(a)-LRx trial that evaluated Lp(a) lowering with an antisense oligonucleotide and presents NHLBI recommendations on Lp(a) lowering.
Lp(a) meeting Elisa Waldmann shows prospective data on reduced CV event rates after regular Lp(a) apheresis in patients with high baseline Lp(a) levels and emphasizes the need of randomized controlled data.
Lp(a) meeting The prevalence of clinical FH was investigated in the Copenhagen General Population Study with adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares possible ways to interpret these results.
EAS 2019 Prof. Evan Stein summarizes novel phase II data of a new 'small binding protein', consisting of adnectin and human albumin, which inhibits PCSK9. The results were such that a phase 3 trial has now started to further study the compound.
EAS 2019 Prof. Chapman lists the newest findings on the associations of Lp(a) levels, PCSK9 inhibitors and CV risk, based on new analyses of the FOURIER and ODYSSEY OUTCOMES trials.
EAS 2019 Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.
Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.
Depending on individual patient characteristics, novel therapeutic approaches can reduce CV risk, particularly in patients at high CV risk. Prof. Landmesser expects that future guidelines will reflect these developments.
In patients with progressive CAD, stabilizing or even regression of disease is possible, targeting a combination of risk factors. Prof. Ray and Prof. Jukema discuss the importance of LDL-c lowering to halt progression.
Several incorrect beliefs exist about cholesterol lowering. Prof. Ray and prof. Montalescot discuss the importance of physician and patient education to improve their knowledge.
New insights into lipid management have emerged since 2016. Prof. Ray discusses with prof. Mach in which respects the guidelines should be changed.
Prof. Masana explains whether achieving very low LDL-c levels with current treatments is safe and might cause any biological problems.
Prof. Kastelein discusses the biology of LDL with prof. Packard and which strategies are available for LDL-c lowering in CVD prevention in high-risk patients.
PCSK9: Outcomes and trials in clinical perspective PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.
PCSK9: Outcomes and trials in clinical perspective There is still a high (residual) risk for future events in many high risk ASCVD patients, despite maximally tolerated statin therapy. Prof. Jukema discusses the use of PCSK9 inhibitors in these high risk patients and the recommendations from international guidelines.
Currently only small numbers of ASCVD patients achieve target LDL-c levels due to certain issues surrounding lipid lowering therapy. Prof. John Kastelein discusses the role of PCSK9 inhibition and future perspectives on lipid lowering.
PCSK9: Outcomes and trials in clinical perspective Prof. Steg summarizes the main results from recent clinical trials with PCSK9 inhibitors and presents some additional analyses in subgroups.
AHA 2018 Lp(a) is a highly prevalent risk factor, with to date no therapy to lower its levels. A phase 2b study now shows that an antisense oligonucleotide potently lowers production of Lp(a), to optimal levels.
AHA 2018 Neil Stone served as vice-president of the new cholesterol guideline. He sums up the main new recommendations based on the latest evidence of recent lipid outcome trials.
Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.
Prof. Jennifer Robinson illustrates the importance of baseline LDL-c levels in CV risk reduction with PCSK9 inhibitors and explains which patients should get this treatment.
In high Lp(a)-associated CV risk patients, reduction of Lp(a) with PCSK9 inhibition lowered this risk, even at very low LDL-c levels.
Whilst lipidology relies mostly on routine laboratory investigations, special investigations are often required to describe specific lipids, lipoproteins and genetic problems. Prof. Marais gives an overview of those investigations.
Trials on lowering Lp(a) have thusfar failed to show a CV outcome benefit. Brian Ference describes a more informative approach to look at Lp(a) data to identify who may benefit from Lp(a)-lowering therapy.
Elevated Lp(a) is now officially considered a genetically determined risk factor for CVD in the USA. Chapman summarizes how Lp(a) is atherogenic and how novel therapies may target this process.
Prof. David Marais reviews the impact of various dietary lipids as they relate to the conventional lipoprotein profile in persons who do not have significant metabolic defects, as well as the impact on persons with metabolic disease.
A prespecified analysis of the ODYSSEY OUTCOME trial showed a bigger treatment effect of alirocumab with no adverse effects on measures of glycemia or new onset diabetes in patients with diabetes compared to those with normoglycemia or pre-diabetes.
Clinical updates in management of cardiovascular risk Using data from large randomized clinical trials and from various cohorts, risk and treatment effects in individual patients can be predicted. Now even lifetime risk and lifetime treatment benefit can be predicted in terms of vascular disease-free life years gained.
Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.
Charlotte Koopal discusses the pathofysiology of familial dysbetalipoproteinemia, how to diagnose the disease and recommendations for treatment.
Clinical updates in management of cardiovascular risk For lowering LDL-c, statins play a major role in both primary and secondary CV prevention in all patients. There is room for improvement with respect to choosing the right dosing regimen.
Prof. Frederick Raal describes the prevalence and phenotypic variability of FH. Novel therapies have changed FH from a lethal disorder to a manageable dyslipidaemia.
VBWG at ACC 2018 Several novel targets have been discovered and new lipid-modifying therapies are being developed to prevent CVD, beyond LDL-c. Elliot Brinton discusses several of these, including omega-3 prescriptions, pemafibrate, apoC3, Lp(a), and shares the first trial results.
VBWG at ACC 2018 In a debate about muscle symptoms in patients on statins, Thompson defended the statement that these symptoms are real by discussing the results of several clinical trials and studies examining the biochemical mechanism.
Atherogenic dyslipidemia increases CV risk in diabetes patients. Prof. Ray discusses the importance of dyslipidemia in these patients, the associated CV risk and new medical therapies to reduce this risk.
Prof. Paul Ridker discusses the insights that originate from the CANTOS trial, in which reducing inflammation with canakinumab reduced CV events. These findings have implications for the management of residual risk.
Prof. Libby discusses IL-1β as a target for atherosclerosis therapy, a strategy that was evaluated in the CANTOS trial, which tested the monoclonal antibody canakinumab.
ACC 2018 Dr. Valentin Fuster explains why he thinks that the results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.
ACC 2018 Prof. Gabriel Steg discusses the 15% reduction of MACE obtained with alirocumab, with a good safety profile. The observed CV benefit was greater in patients who had a higher LDL-c at baseline.
Prof. Libby explains the role of IL-1β in CV disease and the effects of antiinflammatory therapy targeting the IL-1β innate immunity pathway with canakinumab
Prof. Stroes describes the 3 pathways involved in progression of atherosclerosis and new algorithms to reduce residual risk with personalized therapy.
Prof. Wolfgang Koenig explains the role of inflammation in the atherogenic process and how to identify patients with residual inflammatory risk.
Dr. Aruna Pradhan describes the role of triglyceride lowering in reducing CV risk in patients with T2DM.
Prof. John Kastelein describes 3 major disturbances in lipoprotein metabolism contributing to CV risk. Novel therapies are being developed to address residual risk after LDL-c eradication.
Dr. Christopher Cannon explains the CV benefits of CETP inhibition in relation to non-HDL-c reduction
Dr. Samia Mora summarizes the challenges in lipid management with respect to testing and treatment.
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.
Dr. Robert Giugliano summarizes what we have learned over the past decades about the effectiveness and safety of reducing LDL-c to very low values.
AHA 2017 Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.
AHA 2017 PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.
AHA 2017 Subanalysis of FOURIER shows that within the subgroup of patients with prior MI, a subgroup at extra high risk has greater benefit of LDL-c lowering with PCSK9 inhibitor evolocumab.
This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017.
Inflammation Expert Opinions Il prof. Raffaele De Caterina spiega perché CANTOS è uno studio clinico importante. E’ il primo studio clinico che dimostra che un farmaco anti-infiammatorio influenza favorevolmente importanti eventi cardiovascolari, e pertanto può diventare una terapia da inserire nell’armamentario terapeutico in aggiunto agli attuali trattamenti.
Inflammation Expert Opinions Prof. Raffaele de Caterina explains why CANTOS is an important trial. It is the first trial showing that an anti-inflammatory drug can affect important CV outcomes and thus may be a convenient therapy in addition to current treatment strategies.
Inflammation Expert Opinions According to prof. Ulf Landmesser, the CANTOS trial shows that inflammation is crucial for disease progression and that targeting inflammation as a risk factor may have important implications for high-risk populations.
Inflammation Expert Opinions Prof. Ulf Landmesser: Die CANTOS Studie zeigt erstmalig, dass eine Interleukin-1 Beta Inhibition, d.h. eine spezifische Entzündungshemmung, das kardiovaskuläre Risiko nach akutem Koronarsyndrom reduzieren kann.
Inflammation Expert Opinions Prof. Wolfgang Koenig: Die CANTOS Studie belegt dass inflammatorische Prozesse eine kausale Rolle in der Atherogenese spielen. Inhibition der Inflammation führt zu einer weiteren Reduktion des kardiovaskulären Risikos ohne Beeinflussung des Lipidstatus.
Inflammation Expert Opinions Prof. Wolfgang Koenig states that the CANTOS trial shows that inflammation plays a causal role in the atherogenic process. Blocking this inflammation may be an additional treatment option beyond lipid lowering for CV risk reduction.
Inflammation Expert Opinions Lina Badimon explica por qué el bloqueo de la inflamación puede representar un beneficio clínico significativo, debido al importante papel de la inflamación en la formación de la placa aterosclerótica. Los resultados de CANTOS pueden representar el inicio de una nueva era en la prevención cardiovascular.
ESC 2017 Dr. Christie Ballantyne summarises results of diverse studies into various lipid lowering therapies, both approved and experimental strategies, and concludes that they all reinforce current guidelines.
ESC 2017 Virtual histology of components of plaque does not provide additional information in the serial imaging GLAGOV study that showed more coronary atherosclerosis regression when evolocumab was added to intensive statin-treatment.
This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017
ESC 2017 In the REVEAL study, four years after treatment with the CETP inhibitor anacetrapib in addition to high-dose statin, a 9% reduction of the primary endpoint was seen in CVD patients.
ESC 2017 A secondary analysis of the FOURIER analysis divided patients in five categories of achieved LDL-c after 4 weeks of evolocumab treatment. Patients with <0.5 mmol/L showed the lowest CV event rate.
ESC 2017 CETP inhibition is an exception to the rule that LDL reduction leads to CV event reduction. The Mendelian randomization approach was employed to investigate this exception.
ESC 2017 Safe and optimal treatment regimen identified for inclisiran, an siRNA against PCSK9, which is still effective after one year in the ORION-1 trial.
Invitation by Prof Peter Sever to attend the Clinical Dialogue on Lipids & Diabetes to be held on December 6 & 7 in Stratford Upon Avon, United Kingdom
PCSK9 Expert Opinions Prof. Wouter Jukema summarizes the results from FOURIER and SPIRE into the message that PCSK9 inhibition works – even lower is even better; it is safe, and you cannot force biology – it takes a long time to get atherosclerosis, so it will also take some time to get rid of it.
PCSK9 Expert Opinions Prof. Ulf Landmesser states that the results of both FOURIER and SPIRE fit into the concept that lowering LDL to very low levels results in a reduction in CV events
PCSK9 Expert Opinions According to prof. Eric Bruckert, FOURIER is a landmark study that will change clinical practice, especially for patients with the highest risk.
PCSK9 Expert Opinions Prof. Richard Hobbs states that recent data from FOURIER show that effective medical treatment to lower LDL-c reduces endpoints that are important and expensive both for individuals and for health systems.
PCSK9 Expert Opinions Prof. Gilles Lambert describes the development of PCSK9 inhibitors since the discovery in 2002 of PCSK9 as a circulating protein targeting the LDL receptor for degradation. Now in 2017, results of outcome trials with a PCSK9 inhibitor are available.
PCSK9 Expert Opinions By combining all recent insights on treatment with PCSK9 inhibitors, prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.
PCSK9 Expert Opinions Dr. Paul M. Ridker states that from FOURIER and SPIRE it becomes clear that further lowering of LDL-c during a longer period of time safely translates into lower rates of CVD.
PCSK9 Expert Opinions Prof. Kausik Ray describes the practical implications of the PCSK9 outcome trials. In terms of efficacy, there is no J-shaped curve, meaning there is no apparent diminution of benefit to very low LDL
PCSK9 Expert Opinions Prof. Peter Sever describes the results of the FOURIER with respect to safety and efficacy. He puts the data into perspective of other trials and molecules.
ACC 2017 Dr. Paul Ridker discusses data of the SPIRE studies into use of the PCSK9 antibody bococizumab, including the unexpected attenuation of the LDL-c response over time in some patients, as a consequence of development of antibodies against the drug.
ACC 2017 Marc S. Sabatine (Boston) presented the FOURIER-study, which evaluated a PCSK9 inhibitor during two years in over 27000 high-risk patients. LDL-c was reduced by 59%. Both the primary and the secundary clinical endpoint were significantly reduced.
CSI Rome Terje Pedersen defended the 'contra'-argument in a discussion on the use of PCSK9 inhibitors in current clinical practice. He explains to Lotte Koopal and Gijs Berkelmans that while being involved in clinical studies of a PCSK9 antibody, he is still comfortable in the contra-position.
AHA 2016 Prof. John JP Kastelein, MD summarises the promising results of the pivotal GLAGOV and ORION-1 trials, presented at the AHA 2016. In GLAGOV, atheroma regression was seen with evolocumab treatment, and in ORION-1 RNA-interference directed against PCSK9 yielded durable LDL-c lowering effect.
AHA 2016 As a chair of the 2013 ACC/AHA cholesterol guidelines, Neil Stone sheds light on the considerations behind the recommendations on lipid-lowering in the elderly, both for primary and secondary prevention.
AHA 2016 The ORION-1 study evaluated different doses of inclisiran, which prevents hepatic PCSK9 production by RNA interference. With a single injection, about 50% LDL-c reduction was achieved, and maintained through 90 days.
AHA 2016 Prof. Wouter Jukema summarises new insights presented at the AHA, including failing HDL-modifying therapy in the MILANO-PILOT study, a promising effect of a PCSK9 antibody on top of statin on atheroma volume in GLAGOV, and profound LDL-lowering after blocking PCSK9 synthesis in ORION-1.
AHA 2016 Dr. Steve Nissen shares the results of the GLAGOV study, in which evolocumab added to a statin yielded more regression of atheroma volume than statin therapy alone, with an even stronger response in patients with relatively low LDL-c levels.
A mechanism of action animation on the potential role of the inhibition of PCSK9 with a monoclonal antibody
John Kastelein, MD (Amsterdam, The Netherlands) indicates the position of PCSK9-inhibitors in current lipid management, especially in patients with FH.
Participants in the HOPE-3 study were recruited based on their CV risk, without requesting a baseline LDL-c measurement. In the intermediate risk population, randomisation to rosuvastatin yielded a 25% CV risk reduction.
ACC 2016 Jackie Bosch (Hamilton, ONT, Canada) shares the results of the cholesterol-lowering arm of the HOPE-3 study, in which rosuvastatin 10 mg daily yielded a 27% reduction in LDL-c and reduced CV events. The CV benefit was consistent across various subgroups.
ACC 2016 Data from the GAUSS-3 study show that muscle-related statin intolerance is a real problem and PCSK9 inhibition with evolocumab dramatically reduces LDL-c in these patients.
ACC 2016 Prof. Salim Yusuf discusses the results of the HOPE-3 study, which indicates that statins are effective in all patients with intermediate CVD risk, whereas blood pressure lowering is only effective in hypertensive patients.
ACC 2016 Stephen Nicholls discusses the results of the ACCELERATE-study, in which the favourable effects of the CETP-inhibitor evacetrapib on cholesterol did not translate into any reduction in the primary endpoint.
The REACH registry demonstrated that CV risk factors are not adequately controlled worldwide. Prof. Deepak Bhatt (Boston, MA, USA) shares the evidence for preventive strategies and considers how the new PCSK9 inhibitors fit into CV risk management.
Daniel Rader (Philadelphia, PA, USA) looks forward to a future of personalised medicine in FH, which should benefit from specific biomarkers and novel medications, to better treat this common lipid disorder. But first, FH patients need to be better identified.
ISA2015 | Clinical Breakthroughs Dr. Kallend shares data of a phase I trial with ApoA1-Milano-POPC (MDCO216), which was well-tolerated and showed an increase in efflux in patients with recent CAD but who are clinically stable.
Prof. Ray defends the proposition 'Statins are enough for the prevention of CVD' and considers the opposing standpoint in the plenary 'Controversy session' entitled 'Statin therapy vs. novel interventions'. Ray thinks more CVD could be prevented if more people globally would have access to statins. Is it time to add statins to drinking water, then?
ISA2015 | Clinical Breakthroughs Dr. Kontush shared data of a study into the lipidome of HDL particles. HDL particles with phosphatidylserine showed more cardioprotective properties, including antiinflammatory activity, than those without phospatidylserine, both in vitro and in mice.
ISA2015 | Clinical Breakthroughs Dr. Bertrand Cariou presents data of a study that investigated the willingness of patients and physicians to use self-injections (either by prefilled pen or a prefilled syringe) to administer the PCSK9-antibody alirocumab.
Lipid MC 2015 Prof Evan Stein explains why it is important that more international physicians become actively involved in FH research, and he invites those interested to become an FH investigator, which will benefit both patients and the investigator.
ISA2015 | Clinical Breakthroughs Gisette Reyes-Soffer shares the findings on the effect of PCSK9-inhibitor alirocumab on VLDL, IDL, LDL and apoB-metabolism in healthy volunteers.
Lipid MC 2015 Prof. Kausik Ray highlights differences in recommendations between international lipid guidelines, which originate in differences between the scopes of the documents. These differences have consequences for the recommended approach to reduce CV risk in patients.
ISA2015 | Clinical Breakthroughs Harold Bays shares the results of treatment with a new potent chemical entity, cosabutate, hich safely modifies triglyceride and lipid fraction levels in patients with hypertriglyceridaemia.
ISA2015 | Clinical Breakthroughs The ODYSSEY CHOICE I evaluated the efficacy of PCSK9-inhibitor alirocumab given once every four weeks instead of every two weeks. Prof. Eli Roth considers this dosing scheme a good option for patients who prefer monthly injections.
ISA2015 | Clinical Breakthroughs In a pooled analysis of 14 trials with PCSK9-inhibitor alirocumab, in over 5000 patients who achieved LDL <25 of <15 mg/dL, followed for up to 2 years, no safety signals were observed.
ISA2015 | Clinical Breakthroughs Based on the TAUSSIG study, a longer term study of treatment with PCSK9 inhibitor evolocumab in a relatively large group of patients with homozygous FH, prof. Frederick Raal concludes that we now have an additional therapy for these difficult to treat patients.
Lipid MC 2015 Prof. Kausik Ray provides several reasons why non-HDL-c may be a better lipid parameter than LDL-c to assess risk, to identify high-risk patients and guide treatment.
Lipid MC 2015 Dr. Kees Hovingh discusses recent insights into the actual prevalence of homozygous and heterozygous FH, how FH patients can best be identified, and how they should be managed.
ISA2015 | Clinical Breakthroughs Prof. Børge Nordestgaard (Copenhagen, Danmark) discusses results with a novel specific PPAR alpha-modulator that lowers triglycerides, remnant cholesterol and apoCIII, but raises LDL-c. A Danish registry suggests that this combination may actually be a beneficial lipid profile.
ISA 2015 Allyson Morton (Boston, USA) presented a follow-up study of the EVOLVE trial, which showed that omega-3 carboxylic acid treatment reduced apoCIII levels in whole plasma, and in HDL and LDL. LDL levels without apoCIII were reduced, which has a weak relation to CV risk.
ISA 2015 Prof. Martijn Katan (Amsterdam, The Netherlands) responds to the report of the US 2015 Dietary Guidelines Advisory Committee stating that cholesterol intake does not raise serum LDL-c. Older evidence from randomised trials arguing this statement seems to be forgotten.
ISA 2015 In a Clinical Breakthrough Session, dr. Paul Barton Duell (endocrinologist, Portland, USA) presented a striking reduction of MACE with treatment with the antisense oligonucleotide against apoB mRNA mipomersen in a very high risk population.
ISA 2015 During the opening session of ISA2015 in Amsterdam, prof. John Chapman (Paris, France) was awarded with the Antonio M. Gotto, Jr. Prize. He describes how his work on lipid transport, via studying the complexity of lipoprotein particles, has led to the identification of new pharmacological targets.
ISA 2015 During the opening session of ISA2015 in Amsterdam, dr. Harry Davis (Gaithersburg, Maryland, USA) was awarded with the first Endo Award - named after Akira Endo whose work led to the invention of statins. Davis is the father of the LDL-lowering and CV event reducing drug ezetimibe.
Dr. Marc S Sabatine MD, Boston, describes the very compelling results of OSLER studies and the potential for PCSK9 inhibition to reduce major cardiovascular events through robust LDL-c reduction.
Dr. Patrick O' Gara, Boston, and ACC President comments on the results of IMPROVE-IT trial as presented at the AHA meeting in Chicago
Prof. Susekov, Moscow, with a brief update on current challenges to manage CVD in Russia, including some take home messages for Russian physicians
Dr. Michael J Koren MD, Jacksonville, FL, USA, shares his rationale for targeting PCSK9, based on epidemiology and recent clinical developments and discusses implications for future lipid management
Jeanine Roeters van Lennep, MD PhD (Erasmus MC, Rotterdam, The Netherlands) discusses management of homozygous familial hypercholesterolaemia (HoFH).
Lecture by Prof. John Kastelein, Amsterdam, The Netherlands, held during EBAC accredited symposium 'Managing Innovations in lipid management: Evolving insights and implications from PCSK9 research' held during ESC2014 in Barcelona
Prof. John E Deanfield, London introducing the rationale for PCSK9 inhibition with a lecture held during an EBAC accredited symposium on innovations in lipid management at ESC 2014 in Barcelona
A mechanism of action animation on the potential role of the inhibition of PCSK9 with a monoclonal antibody
Prof. Erik Stroes describes new treatments to lower LDL-cholesterol: PCSK9-inhibitors, ApoB antisense and MTP-inhibitors, discussing several studies presented recently at the ACC-congress.
The symposium PCSK9: the new lipid target in preventive cardiology? was held at the congress of the European society of Cardiology (ESC) in Amsterdam on August 31, 2013. A videopresentation from the lecture by Evan Stein Monoclonal antibodies that target PCSK9: What the first clinical trial data are telling? is now available on this website.
Prof. Ingar Holme, Norway, discusses the background and the main results of the SEAS trial.
**Which lipids matter? **Dr. Philip Barter The Heart Research Institute, Sydney Australia